Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : W. Lamm &W. Willenbacher & A. Lang & N. Zojer & E. Müldür & H. Ludwig & B. Schauer-Stalzer & C. C. Zielinski & J. Drach
- چاپ و سال / کشور: 2010
Description
Bortezomib–dexamethasone (Btz/Dex) is an active regimen in patients with multiple myeloma and has been used in few patients with amyloidosis. Here, we report a retrospective evaluation of the efficacy and toxicity of Btz/Dex in 26 patients with AL amyloidosis (AL). Eighteen patients (69%) received Btz/Dex as firstline treatment. Organs most frequently involved were kidneys (100%) and heart (35%); five patients (19%) had less than two organs involved. The overall response rate was 54% (14 of 26 patients), with eight patients (31%) achieving a hematologic complete remission (CR). All patients who reached a CR received Btz/Dex as first-line therapy. Median time to response was 7.5 weeks. Improvement in organ function was noticed in three patients (12%). Median progression-free survival (PFS) and overall survival (OS) was 5.0 and 18.7 months, respectively; in CR patients, however, median PFS and OS have not yet been reached. Toxicities were manageable, with hematological side effects being most common. No grade 3/4 neuropathy was observed. Our results confirm the activity of bortezomib/dexamethasone in patients with AL amyloidosis and suggest that patients achieving a CR have a marked benefit for survival.
Ann Hematol (2011) 90:201–206 DOI 10.1007/s00277-010-1062-6 Received: 5 August 2010 / Accepted: 19 August 2010 / Published online: 7 September 2010
